




Data-Driven Digital Transformation:

The U.S. Food and Drug Administration Center for Drug Evaluation and Research Uses Modern Data Architecture to Bring Safe, High-Quality Healthcare Products to Market Decision Making and Greater Business Agility

"The success of our transformation can be attributed to the way we manage our data. Trusted data from Informatica fulfills our vision and delivers the operational efficiencies we require."

Project Manager
U.S. Food and Drug Administration
Center for Drug Evaluation and Research



Intelligent Disrupter of the Year Winner


Goals Address business challenges arising from globalization, regulation, and market complexities Manage complex product lifecycles more efficiently Improves collaboration and communication with A centralized data warehouse leveraging Oracle enables report generation across the FDA stakeholder groups sharing a single source of truth Create a 360-degree view of the global supply A business-to-business data exchange enables Brings together policy, administrative, scientific, chain associated with products undergoing simplified, secure entry and electronic processing of and operational data consistently across the product regulatory review product information review process

Business Requirements:

- Move from custom, single-use, and project-specific applications to commercial, scalable solutions that have comprehensive and strategic informatics capabilities
- Implement a flexible toolset to address myriad needs across regulatory operations

About U.S. Food and Drug Administration

The Food and Drug Administration is responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; and by ensuring the safety of our nation's food supply, cosmetics, and products that emit radiation.



Informatica Success Story:

The U.S. Food and Drug Administration Center for Drug Evaluation and Research (FDA CDER) faced a growing challenge in the way it managed the development and supply of healthcare products within an increasingly complex regulatory environment. The agency required clearer visibility into the lifecycle of every product under its purview—from supply chain to manufacturing and distribution—to help ensure product safety, quality, and integrity, and improve product tracking and reporting throughout the agency.

Having a clear view of supply chain data was also important to enable the FDA CDER to react faster to product shortfalls by addressing issues in the supply chain or expediting inspections and reviews so that manufacturers could start or accelerate production if necessary. Better data would also allow it to more effectively communicate and coordinate with healthcare providers, patients, and the wider consumer market should shortages occur.

In addition, the FDA CDER faced a growing information management challenge: every year, it received more than 150,000 regulatory submissions; registered over 80,000 firms and product listings; and logged over 1,700,000 adverse event reports. It needed an efficient way to reliably track and manage the volume of data resulting from these transactions.

Data-Driven Strategy

To resolve these business challenges, the FDA CDER embarked on a data-driven digital transformation initiative that enabled it to migrate from site-specific and single-use data solutions to a central, scalable modern data platform with strategic informatics capabilities. The effort involved the integration of data from 12,500 facilities and 21,800 business entities within the supply chain, plus data from 238,000 products and 18,500 ingredients. With 80 percent of active pharmaceutical ingredient manufacturers located outside the United States, this was no small task.

"It was critical for us to connect disparate data sources for full transparency into the lifecycle of each product," says the FDA CDER's project leader. "Visibility is important for safety, efficacy, and quality, and helps us efficiently get products into the hands of those who need them, when they need them."

The FDA CDER built the data platform using flexible, off-the-shelf software. As a first step, Informatica PowerCenter was selected to migrate data from siloed, legacy information sources onto the new platform, while Informatica MDM was used to create a trusted, 360-degree view of supply-chain information and create a single version of truth. For the first time, the agency could see granular data spanning the lifecycle of every product, along with detailed facility data, including identifiers, products or ingredients produced, and position within the supply chain.




Inside The Solution:

- Informatica Master Data Management
- Informatica PowerCenter

"Centralized data management provides accuracy and consistency across all facets of our organization. With Informatica, all our data is in one place, and it can be quickly and easily accessed by stakeholders to support a variety of projects."

Project Manager

U.S. Food and Drug Administration
Center for Drug Evaluation and Research



In addition to Informatica data management capabilities, the new platform incorporated an Oracle data warehouse to support analytics and enable report generation at multiple levels; Apache Solr, for search capabilities; Workfront, to provide a standard project and task management tool for the review process; and EMC Documentum, for the management and storage of documents created during the application process.

Delivering New Efficiencies

Today, the data platform supports business needs across regulatory operations, bringing together policy, administrative, scientific, and operational data across the product review process. It has also improved the quality, speed, predictability, completeness, and transparency of review.

"Centralized data management provides accuracy and consistency across all facets of our organization," says the project leader. "With Informatica, all our data is in one place, and it can be quickly and easily accessed by stakeholders to support a variety of projects."

The new platform has delivered a number of results. A new business-to-business exchange enables simplified, secure entry and processing of electronic submissions. The solution also provides an authoritative source of master data for regulated products, data governance deadlines, synchronization of FDA CDER data, and easy accommodation of regulatory changes. In addition, business process management enables collaboration and communication through work status transparency, standardized and sharable toolsets, and a single, enterprise-wide repository, while business intelligence and publishing functions harness the data warehouse for tasks such as querying, reporting, and analysis.

"The success of our transformation can be attributed to the way we manage our data," concludes the project manager. "Trusted data from Informatica fulfills our vision and delivers the operational efficiencies we required. But we're not done yet—this is a long-term initiative, and the platform will evolve as the market and regulatory landscape changes."

Digital transformation is changing our world. As the leader in enterprise cloud data management, we're prepared to help you intelligently lead the way. To provide you with the foresight to become more agile, realize new growth opportunities or even invent new things. We invite you to explore all that Informatica has to offer—and unleash the power of data to drive your next intelligent disruption. Not just once, but again and again.

Informatica Worldwide Headquarters

2100 Seaport Blvd, Redwood City, CA 94063, USA
Phone: 650.385.5000 | Fax: 650.385.5500 | Toll-free in the US: 1.800.653.3871
informatica.com | facebook.com/InformaticaLLC | linkedin.com/company/informatica | twitter.com/Informatica

© Copyright Informatica LLC 2020. Informatica, the Informatica logo, and PowerCenter are trademarks or registered trademarks of Informatica LLC in the United States and many jurisdictions throughout the world. A current list of Informatica trademarks is available on the web at informatica.com/trademarks.html. Other company and product names may be trade names or trademarks of their respective owners. The information in this documentation is subject to change without notice and provided "AS IS" without warranty of any kind, express or implied.